Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 5, 2017Diseases of the Esophagus

Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKelly R. HaisleyThe Ohio State UniversityKHKyle D. HartOregon Health & Science UniversityNNNima NabavizadehOregon Health & Science University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Haisley et al. (2017) studied this question.

synapsesocial.com/papers/6a0cdc0432b1e5fd57fc0698https://doi.org/10.1093/dote/dox015
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A survey of image‐guided radiation therapy use in the United States2010 · 107 citations
  2. 2Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival*2002 · 70 citations
  3. 3Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer2012 · 5,592 citations
  4. 4Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer2015 · 39 citations